Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2021.09.001
Abstract: BACKGROUND Cabozantinib, a potent multityrosine kinases inhibitor (TKI), has demonstrated overall survival (OS) benefit over everolimus in patients previously treated with VEGFR TKI for metastatic Renal Cell Carcinoma (mRCC). The efficacy of systemic treatments after… read more here.
Keywords: renal cell; cell carcinoma; systemic treatments; cabozantinib failure ... See more keywords